---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036825"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:35:37.125406+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monopar doses first patient with uPAR-targeted radiopharmaceutical MNPR-101-Lu

## Summary
- First patient dosed under US compassionate use protocol for metastatic pancreatic cancer.
- MNPR-101-Lu targets uPAR; infusion well-tolerated with no serious adverse reactions.
- Patient's tumor showed uPAR expression via prior MNPR-101-Zr PET/CT imaging.
- Two Phase 1 studies ongoing in Australia for MNPR-101-Zr (imaging) and MNPR-101-Lu (treatment).
- Company believes this is the world's first dosing of a uPAR-targeted therapeutic radiopharmaceutical.

## SEC filing metadata
- accession: 0001437749-24-036825
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/0001437749-24-036825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/mnpr20241205_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036825
- JSON: https://secwatch.observer/filing/0001437749-24-036825.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.